BioArctic stock
BIOA-B.STSTOBioArctic AB, HealthcareISIN SE0010323311
59Score 59 out of 100, Neutral
Price and trend
64 / 100
Price history
+16% in one yearThe chart shows daily closes over 9 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 1.1% below it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 62).
The price is 14% below its 52-week high. Largest decline in 9 years: 69% (July 2018 to March 2020).
Chart figures for advanced users
- SMA 50$31.13
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$31.76
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)62
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$26.55
- The lowest closing price of the last twelve months.
- Resistance$36.54
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- BioArctic AB belongs to the Biotechnology industry (Sweden) and, with a market value of $2.79B, is number 106 of 289 companies in its industry on MEQIRI.
- For fiscal 2026, analysts expect on average revenue of $133.15M (down 33.6%) and adjusted earnings per share of $0.58 (down 50.2%).
- MEQIRI Score 59 out of 100 (Neutral): rank 277 of 702 in Healthcare, median 53.
Show more
- The P/E is 263.3 (Biotechnology median 21.7, own median of recent years 94.9).
- Our model puts fair value at $50.17, with the price 37% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 100.1% a year since 2020, Biotechnology median 19.4%.Growth 70
- High return on capitalReturn on invested capital 74.5% in fiscal 2025, Biotechnology median −24.3%.Profitability 53
- More cash than debtCash $199.54M, financial debt $9.09M.Stability 84
Weaknesses
- Richly valuedP/E 263.3, Biotechnology median 21.7, own median 94.9.Valuation 41
Its standout strengths are stability and growth, while fundamentals and valuation hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 60 to 59.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
What lowers it
- calm price action
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $35.84 and expensive above $83.62 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $97.75 (cash-flow model) and $2.59 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 7.3%. At 8.3% the fair value would be $41.55, at 6.3% it would be $63.02.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (21.7).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Revenue has grown strongly since 2020, at around 100% per year. From 2020 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 97%, operating 68%, net 51%. Last 12 months: net 11%. From 2020 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 25 Nov 2026in 12 days
- Last reported
- 26 Aug 2026EPS reported −$0.01 (expected −$0.03)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $0.58+0.6%
- Revenue
- $133.15M−0.2%
- Earnings per share
- $0.690.0%
- Revenue
- $172.62M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −5.7%Expectation reiterated: the company still expects to be profitable for full year 2026, with operating costs rising 40% to 60%.
“And we reiterate here that for the full year 2026, the cost -- the operating costs, I should say, are expected to increase by 40% to 60% compared to the year before. So if anything, I would say, in the low range of that spend, but we reiterate roughly 40% to 60%.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 26 Aug 2026 (fiscal Q2 2026), read by AI.
What happened at BioArctic
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 59
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Zai LabZLAB $2.94B50
- ADMA BiologicsADMA $2.94B71
- VericelVCEL $2.93B66
- XencorXNCR $2.86B47
- MBX BiosciencesMBX $2.71B46
- Bavarian NordicBAVA.CO $2.7B71
- Arcus BiosciencesRCUS $2.56B30
- Beam TherapeuticsBEAM $2.49B38
ETFs that hold BioArctic
Held by 13 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares OMX Stockholm Capped UCITS ETFOM3X | 0.16% | 0.10% | €198.93M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.13% | 0.40% | €1.5B |
| iShares Ageing Population UCITS ETF2B77 | 0.12% | 0.40% | €813.42M |
Show 5 more
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.08% | 0.23% | €321.86M |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.08% | 0.30% | €3.45B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.27B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.10% | €395.74M |
| State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR AccZPRX | 0.01% | 0.30% | €813.64M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = SEK 9.9729)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.